DCE-MRI Paramagnetic Agents for Macromolecular Transport Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a non-invasive, effective way to quantify the Enhanced Permeability and Retention (EPR) effect in tumors, essential for assessing macromolecular drug delivery, due to the complexity and heterogeneity of cancerous tissues, leading to inadequate drug penetration and resistance in pharmacological treatments.
Innovation Solution
Development of a DCE-MRI method using paramagnetic contrast agents that mimic the pharmacokinetics of Human Serum Albumin, allowing for non-invasive in vivo estimation of macromolecular solute delivery and permeability in pathological tissues, enabling the identification of penetration-resistant tumors and optimization of anticancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional small molecular chemotherapeutic agents are used, then the treatment can be administered systemically, but the lack of selectivity causes severe side effects and inadequate drug penetration into tumors
Solution Approach 1:
The patent changes the molecular size parameter of the therapeutic agent from small molecular weight (conventional chemotherapy) to large macromolecular weight (40-400 kDa). This parameter change enables the agents to exploit the EPR effect in tumors, achieving selective accumulation in tumor tissues while reducing systemic side effects. The macromolecular agents naturally concentrate in malignant tissues due to enhanced permeability and retention, solving the selectivity problem.
Solution Approach 2:
The patent uses the Enhanced Permeability and Retention (EPR) effect as an intermediary mechanism to achieve selective drug delivery. The EPR effect acts as a natural mediator that facilitates the accumulation of macromolecular agents in tumors through leaky vasculature and impaired lymphatic drainage, eliminating the need for active targeting mechanisms while achieving high tumor selectivity.
2Object-affected harmful factors
If targeted agents with tumor-targeting units are used, then selectivity for tumor regions is improved, but serious side effects and treatment failure have been observed
Solution Approach 1:
Instead of actively targeting tumors using engineered binding units (conventional approach), the patent inverts the strategy by using agents that passively accumulate in tumors through their inherent pharmacokinetic properties. The macromolecular agents naturally concentrate in tumors via the EPR effect, reversing the conventional wisdom that active targeting is necessary for tumor selectivity.
Solution Approach 2:
The patent employs simple macromolecular agents with straightforward pharmacokinetic profiles rather than complex targeted agents. These agents have predictable behavior, clear elimination pathways, and do not require complex targeting mechanisms, reducing the risk of serious side effects while maintaining tumor selectivity through passive accumulation.
3Object-affected harmful factors
If macromolecular drugs are used, then therapeutic efficacy is improved with minimal side effects, but inadequate delivery into pathological tissues causes treatment resistance
Solution Approach 1:
The patent replaces complex active delivery mechanisms (endocytosis, receptor-mediated transport) with passive delivery through the EPR effect. The macromolecular agents utilize the natural leaky vasculature and impaired lymphatic system of tumors to achieve delivery, substituting complex cellular transport mechanisms with a simpler physical phenomenon that ensures adequate penetration into pathological tissues.
4Ease of operation
If DCE-MRI is used to assess macromolecular transport, then non-invasive assessment is achieved, but the complexity and heterogeneity of cancerous tissues makes quantification difficult
Solution Approach 1:
The patent uses contrast agents that replicate the pharmacokinetic behavior of the macromolecular therapeutic agents themselves. By measuring the distribution and clearance of these proxy contrast agents, researchers can indirectly quantify the transport properties of the actual therapeutic agents without needing to directly image the drugs, simplifying the quantification process while maintaining non-invasive assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides reliable, non-invasive assessment of macromolecular drug delivery and tissue permeability, enabling the discrimination of tumors with adequate penetration from those resistant to treatment, thereby improving the effectiveness of macromolecular anticancer therapies.
Implementation Method 1
Development of a DCE-MRI method using paramagnetic contrast agents
Implementation Method 2
assessing the delivery of a macromolecular solute of interest from the pharmacokinetics displayed by a suitable class of paramagnetic contrast agents
Implementation Method 3
assessment of the macromolecular transport within pathologic tissues
Data Source
AI summary
The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies.